A Message from Chris Chen, CEO WuXi Biologics
Chris Chen, Ph.D. and CEO of WuXi Biologics provides the industry with a best practices document from the lessons we learned in China while dealing with the COVID-19 outbreak. Included in his message is a note explaining that because we are fully back to work, we can help keep your mission-critical projects and R&D moving forward.

Just ask us how we can assist during these difficult times (click here to see message) .
WuXi Biologics standardizes a remarkable 12 month “DNA to IND” timeline through its streamlined development platform
Click here to view a 60 second time-lapse video of construction progress at our new site in Dundalk, Ireland
WuXi Biologics’ Subsidiary WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with
a Global Vaccine Leader
WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany
Biologic Products DNA to IND Timeline in 9 Months - Yes It Can Be Done!

WuXi Biologics Congratulates Immutep on Positive Interim data for IMP-321
WuXi Biologics Congratulates OncoImmune on FDA Clearance of IND Application for Next Generation anti-CTLA-4 Antibody ONC-392
WuXi Biologics & Vir Biotechnology Announce Collaboration for
Global Development of Antibodies
to Treat COVID-19
WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development
Read More 

WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases

New Flexible Bispecific Antibody Format Demonstrates Improved Therapeutic Properties and Manufacturability

WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics

I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs
Read More 

Dr. Chris Chen Ph.D., CEO WuXi Biologics, on panel for special on-line forum providing updates on diagnostic, therapeutic and vaccine developments for COVID-19/Coronavirus outbreak

WuXi Biologics Provides Back-to-work Operation Update Related to the Coronavirus Outbreak
WuXi Biologics & Vir Biotechnology Announce Collaboration for
Global Development of Antibodies
to Treat COVID-19
WuXi Biologics Enables Development
of Multiple Neutralizing Antibodies for Novel Coronavirus
Read More 
Visit our Newsletter Archive